Tonix Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes
28 June 2021 - 9:00PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced that Tonix was added to the broad-market Russell 3000®
index and the small-cap Russell 2000® Index, effective after
the U.S. market opens today, June 28, 2021, as part of the annual
reconstitution of the Russell stock indexes.
"Tonix is pleased to be included in the Russell
indexes which reflects our positive achievements and growth over
the past year," stated Seth Lederman, M.D., President and Chief
Executive Officer of Tonix. "These indexes are widely followed and
we look forward to a broader awareness of our Company as a result
of this inclusion.”
Annual reconstitution of the Russell indexes
captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking
them by total market capitalization. Membership in the U.S. all-cap
Russell 3000® Index, which remains in place for one year, means
automatic inclusion in the small-cap Russell 2000® Index, as well
as the appropriate growth and value style indexes. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s US indexes1.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 3000® Index
and Russell 2000® Index and the Russell indexes reconstitution, go
to the “Russell Reconstitution” section on the FTSE Russell
website.
1Source: FTSE Russell
Tonix Pharmaceuticals Holding
Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
small molecules and biologics to treat and prevent human disease
and alleviate suffering. Tonix’s portfolio is primarily composed of
central nervous system (CNS) and immunology product candidates. The
Company’s CNS portfolio includes both small molecules and biologics
to treat pain, neurologic, psychiatric and addiction conditions.
Tonix’s lead CNS candidate, TNX-102 SL1, is in mid-Phase 3
development for the management of fibromyalgia, with positive data
from the Phase 3 RELIEF study reported in December 2020. The
Company expects interim data from the second Phase 3 study, RALLY,
in the third quarter of 2021 and topline data in the first quarter
of 2022. Tonix’s immunology portfolio includes vaccines to prevent
infectious diseases and biologics to address immunosuppression,
cancer, and autoimmune diseases. Tonix’s lead vaccine candidate,
TNX-18002, is a live replicating vaccine based on the horsepox
viral vector platform to protect against COVID-19, primarily by
eliciting a T cell response. Tonix reported positive efficacy data
from animal studies of TNX-1800 in the first quarter of 2021.
TNX-8012, live horsepox virus vaccine for percutaneous
administration, is in development to protect against smallpox and
monkeypox.
1TNX-102 SL is an investigational new drug and
has not been approved for any indication.2TNX-1800 and TNX-801 are
investigational new biologics and have not been approved for any
indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
inclusion in the Russell indexes, risks related to failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations; delays and uncertainties caused by the global COVID-19
pandemic; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval, and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2020, as filed with the Securities and Exchange
Commission (the “SEC”) on March 15, 2021, and periodic reports
filed with the SEC on or after the date thereof. All Tonix's
forward-looking statements are expressly qualified by all such risk
factors and other cautionary statements. The information set forth
herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182
Olipriya Das, Ph.D. (media)Russo
PartnersOlipriya.Das@russopartnersllc.com (646) 942-5588
Peter Vozzo
(investors)Westwicke/ICRpeter.vozzo@westwicke.com(443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024